Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by SundayMovieson May 05, 2023 11:13am
199 Views
Post# 35432965

Deal this summer odds = 100%

Deal this summer odds = 100%
Well, the big question of day will there be a deal. 

The answer is YES. The data set (once officially publish and review at ASCO) will confirm a pretty much one trial de-risked asset for breast with a very nice PFS endpoint.

Someone will license this baby this is a 100% sure.

Will someone be bold and acquire this one, the odds of that moves to 80% in my opinion. Valuation would near 1 billion. 

Will someone put a minority stake here, could be as there potentially so many buyers. An opportunistic minority investor could forck out 50-60 millions to fund ONCY to the finish. 

The sky is very blue here. Going for a sun tan... 


<< Previous
Bullboard Posts
Next >>